Patent EP0156299A2 successfully refreshed from Google Patents.
EP0156299A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
LTR modified viral vaccines
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1985-03-20
•
Granted: —
•
Expires: 2005-03-20
Abstract
Abstract Novel viral polynucleotide sequences and virus preparations recovered therefrom are provided for use as vaccines. In viruses having long terminal repeats (LTRs). where the LTRs includetranscriptional regulatory functions, at least one of the LTR regions is modified to substantially decrease the activity of at least one locus involved in transcriptional regulation. Specifically, feline leukemia virus (FeLV) is modified in the LTR by deleting at least a portion of an enhancer region and the resulting modified FeLV DNA and modified virus derived therefrom shown to be infectious and capable of inducing an immune response in a mammalian host without the serious pathological symptoms normally associated with FeLV. E. coli strain HB101 (pRF3X) was deposited at the American Type Culture Collection on October 14, 1983 and granted accession no. 39470.
Inventors
- 👤 Paul A. Luciw
- 👤 Dino Dina
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 05:31
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C12; C12N; C12N15/00; A; A61; A61K; A61K39/00; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/40; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13022
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
47 words
A polynucleotide sequence capable of providing retroviral infection with diminished pathogenicity in a compatible host, said polynucleotide sequence comprising: the structural genes necessary for replication of a retrovirus; and a defective uncomplemented transcriptional regulatory system originating from in vitro modification, said defective system resulting in attenuated pathogenicity.
Claim 2
Dependent Claim
47 words
A polynucleotide sequence capable of providing retroviral infection with diminished pathogenicity in a compatible host, said polynucleotide sequence comprising: the structural genes necessary for replication of a retrovirus; and a defective uncomplemented transcriptional regulatory system originating from in vitro modification, said defective system resulting in attenuated pathogenicity.
Claim 3
Dependent Claim
28 words
A polynucleotide sequence according to any of Claims 1, 2 or 3, wherein said in vitro modification is a deletion of at least about five bases per strand.
Claim 4
Dependent Claim
26 words
A polynucleotide sequence according to Claim 1 wherein said polynucleotide sequence is at least a part of FeLV which part includes the env gene of FeLV.
Claim 5
Dependent Claim
72 words
A DNA polynucleotide sequence capable.of providing retroviral infection with diminished pathogenicity, said polynucleotide sequence comprising: the structural genes necessary for replication of a retrovirus; a first LTR from the same or different retrovirus having at least a two base deletion per strand in the enhancer sufficient to inactivate the enhancer function region of said first LTR; and any additional LTRs being modified so as to be incapable of restoration of said enhancer.
Claim 6
Dependent Claim
72 words
A DNA polynucleotide sequence capable.of providing retroviral infection with diminished pathogenicity, said polynucleotide sequence comprising: the structural genes necessary for replication of a retrovirus; a first LTR from the same or different retrovirus having at least a two base deletion per strand in the enhancer sufficient to inactivate the enhancer function region of said first LTR; and any additional LTRs being modified so as to be incapable of restoration of said enhancer.
Claim 7
Dependent Claim
69 words
An RNA polynucleotide sequence capable of providing retroviral infection with diminished pathogenicity in a compatible host, said RNA comprising: the structural genes necessary for replication of a retrovirus, the U3 and U5 regions modified by having at least one deletion in at least one of said regions of at least 5 nucleotides, wherein at least one of said deletions originates from in vitro modification, and results in attenuated pathogenicity.
Claim 8
Dependent Claim
69 words
An RNA polynucleotide sequence capable of providing retroviral infection with diminished pathogenicity in a compatible host, said RNA comprising: the structural genes necessary for replication of a retrovirus, the U3 and U5 regions modified by having at least one deletion in at least one of said regions of at least 5 nucleotides, wherein at least one of said deletions originates from in vitro modification, and results in attenuated pathogenicity.
Claim 9
Dependent Claim
15 words
A polynucleotide sequence of about 475-500 bases per strand comprising the LTR of an FeLV.
Claim 10
Dependent Claim
15 words
A polynucleotide sequence of about 475-500 bases per strand comprising the LTR of an FeLV.
Claim 11
Dependent Claim
28 words
A polynucleotide sequence according to Claim 6, wherein said LTR is modified by a deletion of at least one base per strand in the region defining the enhancer.
Claim 12
Dependent Claim
24 words
A vaccine comprising an effective amount of a polynucleotide sequence according to Claim 1, for immunizing a compatible host and a physiologically acceptable carrier.
Claim 13
Dependent Claim
18 words
A vaccine according to Claim 8, wherein said polynucleotide sequence includes at least a part of an FeLV.
Claim 14
Dependent Claim
44 words
A retrovirus preparation capable of providing infection with diminished pathogenicity in a compatible host, said virus preparation obtained by: infecting a susceptible host with the polynucleotide sequence of Claim 1, growing said host to produce retrovirus replication, and recovering said retrovirus from said host.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.